Fetal hemoglobin expression induction

"Fetal hemoglobin expression induction" refers to the therapeutic strategy or biological process aimed at increasing the production of fetal hemoglobin (HbF) in adult erythroid cells. HbF is composed of two alpha and two gamma globin chains; its reactivation can ameliorate symptoms in disorders such as sickle cell disease and β-thalassemia by compensating for defective or deficient adult β-globin. This process is not a single molecular target but involves complex regulation at the genetic and epigenetic levels, including modulation by transcription factors such as BCL11A, NRF2, CREB1/ATF2, chromatin looping between locus control regions and globin promoters, as well as pharmacologic agents like hydroxyurea or DMF that activate relevant pathways to increase γ-globin gene transcription. Genome editing strategies targeting regulatory elements within the β-globin locus have also been shown to induce robust HbF synthesis by altering chromatin architecture or disrupting repressors[1][2][5]. Because "fetal hemoglobin expression induction" describes a therapeutic goal rather than a discrete protein/receptor/enzyme target, it should not be classified as a canonical molecular target. In summary: "fetal hemoglobin expression induction" is not itself a molecule or receptor but rather an important therapeutic approach involving multiple molecular targets for treating certain blood disorders.

Other names

HbF inductionγ-globin gene activationFetal hemoglobin synthesis stimulationInduction of fetal γ-globin expression

Pharmacological activation of transcription factors that upregulate γ-globin gene expression - Example mechanisms include NRF2 pathway activation, histone deacetylase inhibition, and ribonucleotide reductase inhibition.